SBIR/STTR Research Award

A Nanocrystal Biosensor for Detection of Multiple TBI Neurochemical Biomarkers

Award identifier a5ae461dd24d15a8edfb6adeecd64403ffa030bbf7617d2bea991355e807b2c7Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$199,984

Program and phase

SBIR · Phase I

Award year

2007

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
NANOMATERIALS AND NANOFABRICATION LABORATORIES
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): This SBIR proposal intends to develop a nanocrystal biosensor, which is capable of simultaneously detecting and quantifying multiple traumatic brain injury (TBI)-specific biomarkers in relatively small volumes of whole blood (0.1-1 uL). The biosensor design utilizes the well-known size dependent photoluminescence (PL) of the semiconductor nanocrystals to label monoclonal antibodies for these brain injury-specific biomarkers such as {S-100a, D- Dimer, and CRP, etc}. The semiconductor nanocrystals as biolabels make the biosensor able to simultaneously detect multiple TBI-specific neurochemical biomarkers in one setup with a single light source due to their broad excitation spectra, and their narrow, symmetric emission spectra. A membrane filter, immobilized with multiple monoclonal antibodies, will be used as a bioseparator to specifically capture and separate these multiple TBI-specific neurochemical biomarkers from the sample while going through the microflow cell. The simultaneous detection and quantification of multiple brain injury-specific biomarkers will subsequently be accomplished by the differently sized semiconductor nanocrystal biolabeled antibodies. The simultaneous detection of multiple TBI-specific neurochemical biomarkers diminishes the false signal and improves the accuracy in assessing TBI. In comparison to existing technologies such as ELISA, this new technology will be more sensitive, reliable, specific, accurate, portable, robust, inexpensive and rapider to assess TBI.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.